Features
-
The Remarkable History of Hemophilia Care in Canada – a must-read!
Drawing on over fifty years of experience, DR. ROBERT T. CARD and DR. MAN-CHIU POON combine first-hand insights with interviews from more than seventy health care...
-
Gene therapy for hemophilia B one step closer: CSL Behring and pCPA agree on pricing
MONTREAL, October 7, 2025 – CSL Behring Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have announced signing of a Letter of Intent that sets pricing...
-
Reimbursement of Altuviiio recommended, but…
MONTRÉAL, July 3, 2025 – In June, both Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) released...
-
NEW BOOKLET! All About Novel Therapies
The CHS is very proud to present its latest publication, the first component of its brand-new Novel Therapies Education Program. CLICK HERE to access the online booklet.
-
Hemgenix 4-year results show steady durability
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...